Virtu Financial LLC lowered its stake in AveXis Inc (NASDAQ:AVXS) by 68.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,221 shares of the company’s stock after selling 9,047 shares during the quarter. Virtu Financial LLC’s holdings in AveXis were worth $467,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also modified their holdings of the company. Eagle Asset Management Inc. increased its position in AveXis by 123.4% in the 4th quarter. Eagle Asset Management Inc. now owns 354,154 shares of the company’s stock valued at $39,274,000 after acquiring an additional 195,626 shares during the period. State of Wisconsin Investment Board increased its position in shares of AveXis by 55.0% during the 4th quarter. State of Wisconsin Investment Board now owns 24,800 shares of the company’s stock valued at $2,745,000 after purchasing an additional 8,800 shares during the period. Advisory Research Inc. boosted its stake in shares of AveXis by 25.5% during the 4th quarter. Advisory Research Inc. now owns 16,821 shares of the company’s stock worth $1,862,000 after acquiring an additional 3,423 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of AveXis by 9.4% during the 4th quarter. First Trust Advisors LP now owns 27,082 shares of the company’s stock worth $2,997,000 after acquiring an additional 2,325 shares in the last quarter. Finally, First Dallas Securities Inc. bought a new stake in shares of AveXis during the 4th quarter worth $427,000. 82.43% of the stock is owned by hedge funds and other institutional investors.
Shares of AveXis Inc (AVXS) traded up $0.61 during trading on Wednesday, reaching $134.41. 243,466 shares of the company’s stock were exchanged, compared to its average volume of 553,579. The firm has a market capitalization of $4,940.00 and a price-to-earnings ratio of -18.64. AveXis Inc has a 1 year low of $65.23 and a 1 year high of $138.46.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($2.55) EPS for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.91). equities research analysts forecast that AveXis Inc will post -7.63 earnings per share for the current year.
Several analysts have recently commented on AVXS shares. BMO Capital Markets reaffirmed a “buy” rating and issued a $150.00 target price on shares of AveXis in a research report on Thursday, January 18th. Mizuho began coverage on AveXis in a research report on Monday, February 12th. They set a “buy” rating and a $147.00 price objective for the company. William Blair reissued a “buy” rating on shares of AveXis in a research report on Tuesday, January 30th. BidaskClub lowered AveXis from a “hold” rating to a “sell” rating in a report on Thursday, December 14th. Finally, Citigroup set a $132.00 target price on AveXis and gave the company a “buy” rating in a report on Friday, January 5th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $123.90.
In related news, CEO Sean P. Nolan sold 10,000 shares of the business’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $129.47, for a total transaction of $1,294,700.00. Following the transaction, the chief executive officer now directly owns 10,000 shares in the company, valued at $1,294,700. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $109.72, for a total transaction of $195,301.60. Following the completion of the transaction, the vice president now owns 1,780 shares in the company, valued at $195,301.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 65,560 shares of company stock valued at $7,793,030. Insiders own 18.60% of the company’s stock.
WARNING: This piece of content was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/14/virtu-financial-llc-decreases-stake-in-avexis-inc-avxs.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.